Recombinant Fusion Protein for SARS-CoV-2 Antibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for SARS-CoV-2 lack rapid, specific, and economical solutions for detecting anti-SARS-CoV-2 antibodies, which are essential for managing the global health crisis caused by the virus.
Innovation Solution
Development of paper-based diagnostics using recombinant fusion proteins that combine antigenic SARS-CoV-2 proteins with cellulose-binding domains (CBDs), allowing for the specific detection of anti-SARS-CoV-2 antibodies by binding to cellulose-containing substrates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional diagnostic methods are used for SARS-CoV-2 detection, then detection capability is provided, but the methods lack rapidity, specificity, and cost-effectiveness
Solution Approach 1:
The patent employs fusion proteins comprising a SARS-CoV-2 antigenic domain (nucleoprotein or spike protein) fused with a cellulose-binding domain (CBD). This composite structure enables simultaneous specific binding to anti-SARS-CoV-2 antibodies and anchoring to cellulose paper substrates, achieving both rapid detection speed and high detection specificity in a single reagent
Solution Approach 2:
The cellulose-binding domain acts as an intermediary that bridges the SARS-CoV-2 antigen and the paper substrate. The CBD mediates specific binding to cellulose without interfering with the antigen-antibody interaction, enabling rapid immobilization of the detection reagent on the paper while maintaining detection specificity
2Ease of manufacture
If conventional diagnostic methods are used, then detection is possible, but the cost and scalability are insufficient
Solution Approach 1:
The patent utilizes paper-based substrates (cellulose) as disposable, inexpensive test strips. The fusion proteins are immobilized on these single-use paper strips, eliminating the need for expensive reusable equipment while enabling large-scale production and distribution of affordable diagnostic tests for SARS-CoV-2 antibody detection
Solution Approach 2:
The invention extracts only the essential functional domains (antigenic domain and CBD) from complex diagnostic systems, creating a simplified fusion protein that can be produced recombinantly and immobilized on inexpensive paper. This extraction of core functionality enables cost-effective, scalable manufacturing while maintaining detection capability
3Reliability
If fusion proteins with CBD are used, then specific binding to cellulose substrates is achieved, but protein structure and binding affinity must be optimized
Solution Approach 1:
The fusion protein is segmented into distinct functional modules: a SARS-CoV-2 antigenic domain (nucleoprotein or spike protein) and a cellulose-binding domain (CBD), connected by a flexible linker. This segmentation allows independent optimization of each domain's function while maintaining overall protein stability and binding specificity
Solution Approach 2:
The patent optimizes key parameters including the linker length and composition (e.g., Gly-Ser repeats) to ensure proper spacing between the antigenic domain and CBD, maintaining both cellulose binding affinity and antibody binding specificity. The fusion protein sequence and domain orientations are carefully designed to preserve functional properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid, specific, and cost-effective detection of anti-SARS-CoV-2 antibodies, facilitating effective management of the SARS-CoV-2 pandemic by providing a scalable and inexpensive diagnostic tool.
Implementation Method 1
recombinant fusion proteins that combine antigenic SARS-CoV-2 proteins with cellulose-binding domains (CBDs), allowing for the specific detection of anti-SARS-CoV-2 antibodies by binding to cellulose-containing substrates
Implementation Method 2
fusion proteins comprising an antigenic SARS-CoV-2 protein and a cellulose-binding domain (CBD), having the ability to bind anti-SARS-CoV-2 antibodies
Data Source
AI summary
The present disclosure relates to proteins comprising a target-binding domain for detection of anti-SARS-CoV-2 antibodies, methods, compositions and kits thereof.